Hongyin Sun

689 citations
12 papers · 304 indexed · 1 hit paper · h-index 8
Topics
Cancer Immunotherapy and Biomarkers (3 papers)Protein Degradation and Inhibitors (3 papers)Cancer Cells and Metastasis (2 papers)
Partner nations
ChinaCanadaUnited States

In The Last Decade

Hongyin Sun

10 papers receiving 301 citations

Hit Papers

Tumour vasculature at single-cell resolution2024202620252024204060

Peers

Hongyin Sun
Comparison fields: 5 of 66
  • Molecular Biology 180
  • Oncology 79
  • Immunology 70
  • Cancer Research 36
  • Hematology 32
Replace Sathyen A. Prabhu with:
Sathyen A. Prabhu United States
Patricia Costa Brazil
Mai Itoh Japan
Lokman Varışlı Türkiye
Savita Bhalla United States
Yumiko Satoh Japan
Brianne M. Cruickshank Canada
Rebecca E. Parker United States
Tianhang Zhai China
Hongyin Sun relative to Sathyen A. Prabhu United States Sathyen A. Prabhu's profile →
Citations per field
00.5×1.5×2.4×
Sathyen A. Prabhu · 1×
Citations per year

Countries citing papers authored by Hongyin Sun

Since Specialization
Citations

This map shows the geographic impact of Hongyin Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongyin Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongyin Sun more than expected).

Fields of papers citing papers by Hongyin Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongyin Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongyin Sun. The network helps show where Hongyin Sun may publish in the future.

Co-authorship network of co-authors of Hongyin Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Hongyin Sun. A scholar is included among the top collaborators of Hongyin Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongyin Sun. Hongyin Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 0
2 0
3
Tumour vasculature at single-cell resolutionbreakdown →
63
4 7
5 1
6 4
7 11
8 11
9 31
10 115
11 14
12 47

About Hongyin Sun

Hongyin Sun is a scholar working on Oncology, Immunology and Hepatology, having authored 12 papers that have together received 304 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Immunology (70 citations), Oncology (79 citations) and Hematology (32 citations). Hongyin Sun has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Mingzhu Yin, Kanwal Rehman, Muhammad Sajid Hamid Akash, Shuqing Chen, Xiang Chen, Rui Hu, Yao Li, Ying Guo, Qiaohong Yang and Yongguang Tao. Their work appears in journals such as Nature, Nature Communications and Frontiers in Microbiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026